These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33138036)

  • 1. Non-Invasive Measurement of Drug and 2-HG Signals Using
    Wenger KJ; Richter C; Burger MC; Urban H; Kaulfuss S; Harter PN; Sreeramulu S; Schwalbe H; Steinbach JP; Hattingen E; Bähr O; Pilatus U
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
    Pellegatta S; Valletta L; Corbetta C; Patanè M; Zucca I; Riccardi Sirtori F; Bruzzone MG; Fogliatto G; Isacchi A; Pollo B; Finocchiaro G
    Acta Neuropathol Commun; 2015 Jan; 3():4. PubMed ID: 25849072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
    Wick A; Bähr O; Schuler M; Rohrberg K; Chawla SP; Janku F; Schiff D; Heinemann V; Narita Y; Lenz HJ; Ikeda M; Ando Y; Wick W; Steinbach JP; Burger MC; Wenger K; Lassen U; Sankhala KK; Roggia C; Genvresse I; Munhoz C; Rentzsch C; Reschke S; Langer S; Wagner M; Kaulfuss S; Cai C; Lagkadinou E; Jeffers M; Peña C; Tabatabai G
    Clin Cancer Res; 2021 May; 27(10):2723-2733. PubMed ID: 33622704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
    Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
    Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.
    Chaturvedi A; Gupta C; Gabdoulline R; Borchert NM; Goparaju R; Kaulfuss S; Görlich K; Schottmann R; Othman B; Welzenbach J; Panknin O; Wagner M; Geffers R; Ganser A; Thol F; Jeffers M; Haegebarth A; Heuser M
    Haematologica; 2021 Feb; 106(2):565-573. PubMed ID: 32241846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma.
    Nakagawa M; Yamaguchi M; Endo M; Machida Y; Hattori A; Tanzawa F; Tsutsumi S; Kitabayashi I; Kawai A; Nakatani F
    J Bone Oncol; 2022 Jun; 34():100430. PubMed ID: 35493690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Reprogramming of Autophagy Drives Mutant IDH1 Glioma Progression and Response to Radiation.
    Núñez FJ; Banerjee K; Mujeeb AA; Mauser A; Tronrud CE; Zhu Z; Taher A; Kadiyala P; Carney SV; Garcia-Fabiani MB; Comba A; Alghamri MS; McClellan BL; Faisal SM; Nwosu ZC; Hong HS; Qin T; Sartor MA; Ljungman M; Cheng SY; Appelman HD; Lowenstein PR; Lahann J; Lyssiotis CA; Castro MG
    bioRxiv; 2024 Mar; ():. PubMed ID: 38559270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and Preclinical Evaluation of
    Cologni R; Holschbach M; Schneider D; Bier D; Schulze A; Stegmayr C; Endepols H; Ermert J; Neumaier F; Neumaier B
    Molecules; 2024 Aug; 29(16):. PubMed ID: 39203017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Invasive Prediction of
    Bumes E; Wirtz FP; Fellner C; Grosse J; Hellwig D; Oefner PJ; Häckl M; Linker R; Proescholdt M; Schmidt NO; Riemenschneider MJ; Samol C; Rosengarth K; Wendl C; Hau P; Gronwald W; Hutterer M
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33212941
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
    Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
    Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
    Heuser M; Palmisiano N; Mantzaris I; Mims A; DiNardo C; Silverman LR; Wang ES; Fiedler W; Baldus C; Schwind S; Pardee T; Perl AE; Cai C; Kaulfuss S; Lagkadinou E; Rentzsch C; Wagner M; Wilkinson G; Wu B; Jeffers M; Genvresse I; Krämer A
    Leukemia; 2020 Nov; 34(11):2903-2913. PubMed ID: 32733012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Correlation of In Vivo MR Spectroscopy and Ex Vivo 2-Hydroxyglutarate Concentration for the Prediction of Isocitrate Dehydrogenase Mutation Status in Diffuse Glioma.
    van Dijken BRJ; Jeltema HR; Kłos J; van Laar PJ; Enting RH; Maatman RGHJ; Bijsterveld K; Den Dunnen WFA; Dierckx RA; Sijens PE; van der Hoorn A
    Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma.
    Radoul M; Hong D; Gillespie AM; Najac C; Viswanath P; Pieper RO; Costello JF; Luchman HA; Ronen SM
    Metabolites; 2021 Feb; 11(2):. PubMed ID: 33668509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.
    Esmaeili M; Hamans BC; Navis AC; van Horssen R; Bathen TF; Gribbestad IS; Leenders WP; Heerschap A
    Cancer Res; 2014 Sep; 74(17):4898-907. PubMed ID: 25005896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo Metabolic Profiles as Determined by
    Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
    Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
    Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
    Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
    Konteatis Z; Artin E; Nicolay B; Straley K; Padyana AK; Jin L; Chen Y; Narayaraswamy R; Tong S; Wang F; Zhou D; Cui D; Cai Z; Luo Z; Fang C; Tang H; Lv X; Nagaraja R; Yang H; Su SM; Sui Z; Dang L; Yen K; Popovici-Muller J; Codega P; Campos C; Mellinghoff IK; Biller SA
    ACS Med Chem Lett; 2020 Feb; 11(2):101-107. PubMed ID: 32071674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Hydroxyglutarate as an MR spectroscopic predictor of an IDH mutation in gliomas.
    Bauer J; Raum HN; Kugel H; Müther M; Mannil M; Heindel W
    Rofo; 2024 Dec; 196(12):1228-1235. PubMed ID: 38648790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.